GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene SA (XPAR:TNG) » Definitions » Total Equity

Transgene (XPAR:TNG) Total Equity : €15.61 Mil (As of Dec. 2023)


View and export this data going back to 1998. Start your Free Trial

What is Transgene Total Equity?

Transgene's total equity for the quarter that ended in Dec. 2023 was €15.61 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Transgene Total Equity Historical Data

The historical data trend for Transgene's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transgene Total Equity Chart

Transgene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 65.70 50.72 67.21 37.84 15.61

Transgene Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 67.21 54.40 37.84 21.96 15.61

Transgene Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Transgene's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=45.217-29.605
=15.61

Transgene's Total Equity for the quarter that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=45.217-29.605
=15.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Transgene Total Equity Related Terms

Thank you for viewing the detailed overview of Transgene's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Transgene (XPAR:TNG) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene SA (XPAR:TNG) » Definitions » Total Equity
Comparable Companies
XPAR:ADOC XPAR:DBV XPAR:MAAT XPAR:IVA XPAR:AELIS XPAR:OSE XPAR:ALVAL XPAR:GNFT XPAR:GNRO XPAR:IPH OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
TGNA:Germany
Address
400 Boulevard Gonthier d’Andernach, Parc d’Innovation - CS80166, Illkirch-Graffenstaden, FRA, 67400
Website
https://www.transgene.fr
Transgene SA is a biotechnology company. It is involved in the business of discovering and focusing immune-targeted therapies for the treatment of cancer and infectious diseases. The company's clinical-stage programs are TG4010 for non-small cell lung cancer and Pexa-vec for liver cancer. Its product pipeline includes TG4001, TG1050, TG6002 etc. It is engaged in clinical research and development of therapeutic vaccines and immunotherapeutic products.

Transgene (XPAR:TNG) Headlines

No Headlines